@NippLeZz Thanks for your concern. Regardless of whether what you say is true or false, this is a risk i am willing to take. So, no worries for me....

@Miz Raya Bloom Ya saya pun dah pening tiap-tiap hari memantau harga saham Kanger yang enggan bergerak...Tak cukup vitamin...

Hopefully starting tomorrow or next week, company insider will start to push the price upwards in order to please the 3rd party investors of the PP...

@BigBladd Yea, this Kanger is Funny...

Looks like what i said previously below is correct. This should be the final tranche of PP. Now PP is COMPLETE.

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ? No
Types of corporate proposal Private Placement
Details of corporate proposal Private Placement of up to 20% of the total number of issued shares of Kanger
No. of shares issued under this corporate proposal 7,759,261
Issue price per share ($$) Malaysian Ringgit (MYR) 0.1593
Par Value($$) (if applicable) Malaysian Ringgit (MYR) 0.000
Latest issued share capital after the above corporate proposal in the following
Units 2,263,027,807
Issued Share Capital ($$) Malaysian Ringgit (MYR) 224,195,582.200
Listing Date 11 Dec 2020


Announcement Info
Company Name KANGER INTERNATIONAL BERHAD
Stock Name KANGER
Date Announced 10 Dec 2020
Category Additional Listing Announcement /Subdivision of Shares
Reference Number ALA-10122020-00017

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3112642

------------------------

@mikho69 @UlarSawa After digging up all the bursa announcements, the answer is as follows : Total number of shares to be issued for PP is 386,970,684 (Please refer to the link below). Hence, after deducting the no. of PP shares issued for 1st tranche ie. 183,237,544 and no. of PP shares issued for 2nd tranche ie. 195,973,879, the remaining balance should be only 7,759,261 shares left.

However, if we take into account what @x3shphere mentioned above regarding the conversion of redeemable convertible notes (RCN) ie 3,703,703 shares, then total remaining would be 7,759,261 PP + 3,703,703 RCN = 11,462,964 remaining shares (Disclaimer : I have no idea what RCN is and whether it should be added to the number of remaining private placement shares. Perhaps some expert here can enlighten us on this matter)

Kanger should be making the announcement soon regarding the number of shares issued for the 3rd tranche which would be the final tranche and private placement would be complete.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3103957

Govt awaits Agong's consent for edict on Covid-19 vaccine, says Zulkifli

https://www.theedgemarkets.com/article/govt-awaits-agongs-consent-edict-covid19-vaccine-says-zulkifli

Govt awaits Agong's consent for edict on Covid-19 vaccine, says Zulkifli

https://www.theedgemarkets.com/article/govt-awaits-agongs-consent-edict-covid19-vaccine-says-zulkifli

Govt awaits Agong's consent for edict on Covid-19 vaccine, says Zulkifli

https://www.theedgemarkets.com/article/govt-awaits-agongs-consent-edict-covid19-vaccine-says-zulkifli

Govt awaits Agong's consent for edict on Covid-19 vaccine, says Zulkifli

https://www.theedgemarkets.com/article/govt-awaits-agongs-consent-edict-covid19-vaccine-says-zulkifli

Govt awaits Agong's consent for edict on Covid-19 vaccine, says Zulkifli

https://www.theedgemarkets.com/article/govt-awaits-agongs-consent-edict-covid19-vaccine-says-zulkifli

Govt awaits Agong's consent for edict on Covid-19 vaccine, says Zulkifli

https://www.theedgemarkets.com/article/govt-awaits-agongs-consent-edict-covid19-vaccine-says-zulkifli

Spoke too soon. Today, Kanger will close at 0.165....

Today Kanger will close at the same price as yesterday ie 0.170....

@Jolly Nobody here can answer your question why it is not moving despite all the good news regarding bamboo, vaccines etc....We are equally perplexed here...We can only play the waiting game and hope for the best..

I wonder whether UlarSawa bought any stocks after asking so many questions here as well as in other counter forums as well or is he just asking for fun?

LOLOL

@UlarSawa Sayonaraaa.....

@Noobie Actually to be precise, there are 2 types of vaccines used to protect against polio disease ie. Attenuated oral polio vaccine (OPV) and Inactivated polio vaccine (IPV). So Sinopharm vaccine is using the same technology/ platform as the Inactivated polio vaccine.

@UlarSawa If i don't post any vaccine news, make sure you post some bamboo news okay?

@paktua73 Sinopharm, Sinovac and Cansino vaccine are Halal....

-----------

Bio Farma President Director Honesti Basyir said that the MUI is involved in the data examination process to ensure that vaccines produced by Sinovac, CanSino, and G24/Sinopharm are halal. “Abu Dhabi (UAE)’s ulema council has announce that there is no issue with the halal status of the G24 vaccine,” he said.

Sumber: https://setkab.go.id/en/govt-involves-mui-to-ensure-halal-covid-19-vaccine/

Advantages of Sinopharm Vaccine....

----------

Sinopharm’s vaccines are both made from coronaviruses that have been killed or weakened, a technique that has been used for decades in the influenza and polio vaccines, for example. By comparison, Moderna’s and Pfizer’s vaccines use a technology that has never before been approved for widespread use.

Another advantage of the inactivated vaccines being developed by Sinopharm is that they tend to have fewer adverse effects after immunization, according to Florian Krammer, an immunologist at the Icahn School of Medicine at Mount Sinai in New York. He said more clarity on the trials in the Emirates would be welcome, but expressed confidence in the vaccine’s initial results.

https://www.nytimes.com/2020/12/09/business/china-coronavirus-vaccine-united-arab-emirates.html?auth=login-google

Advantages of Sinopharm Vaccine....

----------

Sinopharm’s vaccines are both made from coronaviruses that have been killed or weakened, a technique that has been used for decades in the influenza and polio vaccines, for example. By comparison, Moderna’s and Pfizer’s vaccines use a technology that has never before been approved for widespread use.

Another advantage of the inactivated vaccines being developed by Sinopharm is that they tend to have fewer adverse effects after immunization, according to Florian Krammer, an immunologist at the Icahn School of Medicine at Mount Sinai in New York. He said more clarity on the trials in the Emirates would be welcome, but expressed confidence in the vaccine’s initial results.

https://www.nytimes.com/2020/12/09/business/china-coronavirus-vaccine-united-arab-emirates.html?auth=login-google

vaccine counter volume relatively lower today for some reason...

@Bigbladd Not everyone here is "trapped". I bought at a relatively lower price plus i am using my spare cash here. I can leave whenever i want to but i choose not to leave for now. I will hold for as long as i want to see how far it can go or not go...

Didnt know KYY is in Kanger...

To be fair glove counters are green today so that might affect vaccines theme as well....

Bamboo to the rescue !

Financial health poor this year due to Covid....We shall see the financial health next year whether it improves...

Hopefully they will terminate Kstar agreement...and just maintain Zuellig Pharma...

Yes, Kstar is a weird choice indeed....

@18KHarmoni Agreed...

@18KHarmoni I agree, they should just collaborate with Zuellig Pharma alone...but unfortunately we have no say in this matter...

@UlarSawa The only reason i share on vaccine is because that is my area of expertise...

@UlarSawa No harm sharing info on both bamboo and vaccine. You are welcome to share info on bamboo...

@UlarSawa Not saying the company's performance is good but i think the reason why Kanger collaborated with Kstar is because both also HQ in China. Kanger could be favouring China based company..

@UlarSawa

“For a start, we will be establishing a mobile sales and marketing team to approach the private clinics throughout Malaysia,” K-Star’s executive chairman Ding Jianping pointed out.

According to Ding, a key person who will be spearheading this initiative is K-Star’s executive director Koo Kien Yoon who was the executive director of Biosis Group Bhd for three years in 2013 to 2016 where he spearheaded the sales, marketing and distribution of healthcare and pharmaceutical products for Biosis.

“With his established business network as well as personal experience in the industry, K-Star would be able to leverage Koo’s prior experience and knowledge to establish a leading market position in this business of distributing COVID-19 vaccines to private clinics in Malaysia,” noted Ding.

https://focusmalaysia.my/markets/k-star-gears-up-to-distribute-covid-19-vaccines-to-private-clinics/

@UlarSawa Zuellig Pharma is very established and experienced in vaccine distribution. Nothing to worry about. Zuellig Pharma is the LARGEST vaccine distributor in Malaysia and in Asia. I

---------------

Kanger International Bhd has roped in Zuellig Pharma Sdn Bhd and K-Star Sport Ltd to collaborate on the distribution of Covid-19 vaccines in Malaysia.

The vaccine and other products are developed by state-owned China National Pharmaceutical Group Corp (Sinopharm).

In a filing with Bursa Malaysia today, Kanger said it has entered into a memorandum of understanding (MoU) with Zuellig Pharma, the largest vaccine distributor in Malaysia and in Asia, to facilitate the import, warehousing and distribution of Covid-19 vaccines in Malaysia.

Separately, Kanger announced that it has also entered into an MoU with K-Star to appoint the latter as the sales agent of Covid-19 vaccines for private clinics in Malaysia.

Kanger said both MoUs will add value to the group as it is now focused on expanding its business into the healthcare industry, which includes the distribution of Covid-19 vaccines, and is looking for a well-established logistics and distribution provider.

https://www.theedgemarkets.com/article/kanger-ropes-more-collaborators-help-distribute-covid19-vaccines

@bowman Yes, i agree. Their investor-relations department is doing a lousy job...

@UlarSawa Too early to say whether vaccine distribution will be profitable or not. We have to wait for approval from China, maybe WHO and NPRA first. We shall see later. Of course bamboo will still make the most profit.....

@satriahijau

Kanger International Bhd has roped in Zuellig Pharma Sdn Bhd and K-Star Sport Ltd to collaborate on the distribution of Covid-19 vaccines in Malaysia.

The vaccine and other products are developed by state-owned China National Pharmaceutical Group Corp (Sinopharm).

In a filing with Bursa Malaysia today, Kanger said it has entered into a memorandum of understanding (MoU) with Zuellig Pharma, the largest vaccine distributor in Malaysia and in Asia, to facilitate the import, warehousing and distribution of Covid-19 vaccines in Malaysia.

Separately, Kanger announced that it has also entered into an MoU with K-Star to appoint the latter as the sales agent of Covid-19 vaccines for private clinics in Malaysia.

Kanger said both MoUs will add value to the group as it is now focused on expanding its business into the healthcare industry, which includes the distribution of Covid-19 vaccines, and is looking for a well-established logistics and distribution provider.

https://www.theedgemarkets.com/article/kanger-ropes-more-collaborators-help-distribute-covid19-vaccines

Yes, agreed. We need to see the actual clinical data to confirm this. This is because Pfizer (94%), Moderna (95%) and AstraZeneca (70%) efficacy rates actually refers to prevention of symptomatic disease and NOT prevention of asymptomatic disease or prevention of Covid-19 infection itself. The efficacy rate in prevention of asymptomatic disease or prevention of Covid-19 infection will certainly be lower than that. So with that being said, hopefully Sinopharm clinical data will be released soon and will confirm this...

------------

If CNBG’s (Sinopharm) vaccine indeed prevented 86% of infections and 100% of symptomatic disease, it would stand out as the BEST EFFICACY data yet. But the few details of the trial’s protocol available indicate it primarily aimed to evaluate the vaccine’s ability to prevent cases of disease, not infection.

https://www.sciencemag.org/news/2020/12/great-efficacy-claimed-another-covid-19-vaccine-one-china

Yes, hopefully. Subsequently, they can proceed to apply for WHO approval...

It is also a delicacy in several other countries

Totally agree with dr Noor hisham on this “ “The news is not true at all. If we see, China has come out with prequalified vaccines for the World Health Organisation (WHO), for example, vaccines for influenza, polio, hepatitis A, and japanese encephalitis.

“So they have experience with manufacturing vaccines,” he said during a press conference today. ”

Sinopharm has produced who prequalified vaccines before

https://www.msn.com/en-my/news/national/dr-noor-hisham-rubbishes-report-claiming-chinese-vaccines-unsafe/ar-BB1bLXkq?ocid=msedgntp

They should hire us as their PR haha...

Bioleaders in discussion with Sinopharm to bring Chinese vaccines in Korea

https://www.koreabiomed.com/news/articleView.html?idxno=9867

United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19

TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.

The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.

The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.

The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”

The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.

https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c

United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19

TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.

The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.

The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.

The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”

The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.

https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c

AstraZeneca vaccine details published in Lancet, but data suggests need for more trials

LONDON — Scientists at AstraZeneca and the University of Oxford on Tuesday became the first vaccine developers to publish their full data in a peer-reviewed scientific journal, confirming earlier claims that the vaccine is 70 percent effective overall.

https://www.washingtonpost.com/world/europe/astrazeneca-lancet-covid-vaccine-oxford/2020/12/08/482ca0f0-34b5-11eb-9699-00d311f13d2d_story.html